Hepatitis Monthly

Published by: Kowsar
Corrected Proof scheduled for 18 (8)

Efficacy and Side Effects of Sofosbuvir and Daclatasvir for Treatment of Hepatitis C in Thalassemia Major Patients with Treatment Experience of Interferon-Based Regimens

Jamshid Vafaeimanesh 1 , 2 , Fahimeh Safarnezhad Tameshkel 1 , Hossein Ajdarkosh 1 , Azita Azarkeyvani 3 , Mahmoodreza Khoonsari 1 , Amirhossein Faraji 1 , Masoudreza Sohrabi 1 , Sima Aten 1 , Hossein Keyvani 1 and Farhad Zamani 1 , *
Authors Information
1 Gastrointestinal and Liver Disease Research Center, Iran University of Medical Sciences, Tehran, IR Iran
2 Gastroenterology and Hepatology Disease Research Center, Qom University of Medical Sciences, Qom, IR Iran
3 Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Department of Thalassemia Clinic, Tehran, IR Iran
Article information
  • Hepatitis Monthly: , In Press (In Press); e66419
  • Published Online: July 11, 2018
  • Article Type: Research Article
  • Received: January 17, 2018
  • Revised: June 5, 2018
  • Accepted: June 9, 2018
  • DOI: 10.5812/hepatmon.66419

To Cite: Vafaeimanesh J, Safarnezhad Tameshkel F, Ajdarkosh H, Azarkeyvani A, Khoonsari M, et al. Efficacy and Side Effects of Sofosbuvir and Daclatasvir for Treatment of Hepatitis C in Thalassemia Major Patients with Treatment Experience of Interferon-Based Regimens, Hepat Mon. Online ahead of Print ;In Press(In Press):e66419. doi: 10.5812/hepatmon.66419.

Copyright © 2018, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. Akin M, Buldukoglu OC, Adanir H, Suleymanlar I, Dincer D, Yildirim B. Effectiveness and safety of sofosbuvir/ledipasvir ± ribavirin treatment in liver and/or renal transplant patients with chronic hepatitis C: A single-center experience. SAGE Open Med. 2018;6. doi: 10.1177/2050312118781416. [PubMed: 29899985]. [PubMed Central: PMC5992795].
  • 2. Geddawy A, Ibrahim YF, Elbahie NM, Ibrahim MA. Direct acting anti-hepatitis C virus drugs: clinical pharmacology and future direction. J Transl Int Med. 2017;5(1):8-17. doi: 10.1515/jtim-2017-0007. [PubMed: 28680834]. [PubMed Central: PMC5490957].
  • 3. Naghipour-Khalkhaliani D, Behzadpour D, Mousavi Nasab SD. Distribution of Hepatitis C Virus Genotypes in Rasht, Capital City of Guilan Province, Northern Part of Iran. Hepat Mon. 2018;18(2). doi: 10.5812/hepatmon.62030.
  • 4. Ansari SH, Shamsi TS, Ashraf M, Bohray M, Farzana T, Khan MT, et al. Molecular epidemiology of beta-thalassemia in Pakistan: far reaching implications. Int J Mol Epidemiol Genet. 2011;2(4):403-8. [PubMed: 22200002]. [PubMed Central: PMC3243455].
  • 5. Jafroodi M, Davoudi-Kiakalayeh A, Mohtasham-Amiri Z, Pourfathollah AA, Haghbin A. Trend in Prevalence of Hepatitis C Virus Infection among beta-thalassemia Major Patients: 10 Years of Experience in Iran. Int J Prev Med. 2015;6:89. doi: 10.4103/2008-7802.164832. [PubMed: 26445636]. [PubMed Central: PMC4587076].
  • 6. Khodaei GH, Farbod N, Zarif B, Nateghi S, Saeidi M. Frequency of thalassemia in Iran and Khorasan Razavi. Int J Pediatr. 2013;1(1):45-50.
  • 7. Vidja PJ, Vachhani JH, Sheikh SS, Santwani PM. Blood transfusion transmitted infections in multiple blood transfused patients of Beta thalassaemia. Indian J Hematol Blood Transfus. 2011;27(2):65-9. doi: 10.1007/s12288-011-0057-3. [PubMed: 22654294]. [PubMed Central: PMC3136674].
  • 8. El-Faramawy AA, El-Rashidy OF, Tawfik PH, Hussein GH. Transfusion transmitted hepatitis: where do we stand now? A one center study in upper egypt. Hepat Mon. 2012;12(4):286-91. doi: 10.5812/hepatmon.852. [PubMed: 22690237]. [PubMed Central: PMC3360939].
  • 9. Ataei B, Hashemipour M, Kassaian N, Hassannejad R, Nokhodian Z, Adibi P. Prevalence of anti HCV infection in patients with Beta-thalassemia in isfahan-iran. Int J Prev Med. 2012;3(Suppl 1):S118-23. [PubMed: 22826753]. [PubMed Central: PMC3399295].
  • 10. Safarnezhad Tameshkel F, Karbalaie Niya MH, Sohrabi M, Panahi M, Zamani F, Imanzade F, et al. Polymorphism of IL-28B Gene (rs12979860) in HCV Genotype 1Patients Treated by Pegylated Interferon and Ribavirin. Iran J Pathol. 2016;11(3):216-21. [PubMed: 27799970]. [PubMed Central: PMC5079454].
  • 11. Mahmud S, Akbarzadeh V, Abu-Raddad LJ. The epidemiology of hepatitis C virus in Iran: Systematic review and meta-analyses. Sci Rep. 2018;8(1):150. doi: 10.1038/s41598-017-18296-9. [PubMed: 29317673]. [PubMed Central: PMC5760657].
  • 12. Ansar MM, Kooloobandi A. Prevalence of hepatitis C virus infection in thalassemia and haemodialysis patients in north Iran-Rasht. J Viral Hepat. 2002;9(5):390-2. [PubMed: 12225335].
  • 13. Somi MH, Ardalan MR, Sokhanvar H, Farhang S, Pouri A. Hepatitis C virus infection in dialysis centers of Tabriz, Iran: a multicenter study. Iran J Clin Infect Dis. 2007;2(1):23-6.
  • 14. Agarwal MB, Malkan GH, Bhave AA, Vishwanathan C, Billa V, Dube SR, et al. Antibody to hepatitis-C virus in multi-transfused thalassaemics--Indian experience. J Assoc Physicians India. 1993;41(4):195-7. [PubMed: 8270554].
  • 15. Mirmomen S, Alavian SM, Hajarizadeh B, Kafaee J, Yektaparast B, Zahedi MJ, et al. Epidemiology of hepatitis B, hepatitis C, and human immunodeficiency virus infecions in patients with beta-thalassemia in Iran: a multicenter study. Arch Iran Med. 2006;9(4):319-23. [PubMed: 17061602].
  • 16. Mahmoud RA, El-Mazary AA, Khodeary A. Seroprevalence of Hepatitis C, Hepatitis B, Cytomegalovirus, and Human Immunodeficiency Viruses in Multitransfused Thalassemic Children in Upper Egypt. Adv Hematol. 2016;2016:9032627. doi: 10.1155/2016/9032627. [PubMed: 26989417]. [PubMed Central: PMC4773519].
  • 17. al-Fuzae L, Aboolbacker KC, al-Saleh Q. beta-Thalassaemia major in Kuwait. J Trop Pediatr. 1998;44(5):311-2. doi: 10.1093/tropej/44.5.311. [PubMed: 9819498].
  • 18. al-Mahroos FT, Ebrahim A. Prevalence of hepatitis B, hepatitis C and human immune deficiency virus markers among patients with hereditary haemolytic anaemias. Ann Trop Paediatr. 1995;15(2):121-8. [PubMed: 7677412].
  • 19. Al-Sheyyab M, Batieha A, El-Khateeb M. The prevalence of hepatitis B, hepatitis C and human immune deficiency virus markers in multi-transfused patients. J Trop Pediatr. 2001;47(4):239-42. doi: 10.1093/tropej/47.4.239. [PubMed: 11523766].
  • 20. Zamani F, Sohrabi M, Poustchi H, Keyvani H, Saeedian FS, Ajdarkosh H, et al. Prevalence and risk factors of hepatitis C virus infection in amol city, north of iran: a population-based study (2008-2011). Hepat Mon. 2013;13(12). e13313. doi: 10.5812/hepatmon.13313. [PubMed: 24358039]. [PubMed Central: PMC3867021].
  • 21. Sandoughdaran S, Alavian SM, Sharafi H, Behnava B, Salimi S, Mehrnoush L, et al. Efficacy of Prolonged Treatment With Pegylated Interferon (Peg-IFN) and Ribavirin in Thalassemic Patients With Hepatitis C Who Relapsed After Previous Peg-IFN-Based Therapy. Hepat Mon. 2015;15(1). e23564. doi: 10.5812/hepatmon.23564. [PubMed: 25741371]. [PubMed Central: PMC4344648].
  • 22. Hesamizadeh K, Sharafi H, Rezaee-Zavareh MS, Behnava B, Alavian SM. Next Steps Toward Eradication of Hepatitis C in the Era of Direct Acting Antivirals. Hepat Mon. 2016;16(4). e37089. doi: 10.5812/hepatmon.37089. [PubMed: 27275164]. [PubMed Central: PMC4893415].
  • 23. Karbalaie Niya MH, Salman-Tabar S, Bokharaei-Salim F, Behmanesh M, Keyvani H. Prevalence of resistant associated variants (RAVs) in the naive HCV patient candidate for direct acting antiviral (DAA) therapy. Microb Pathog. 2017;105:166-70. doi: 10.1016/j.micpath.2017.01.060. [PubMed: 28161357].
  • 24. Sharafi H, Nikbin M, Alavian SH, Behnava B, Alavian SM. Efficacy and safety of generic sofosbuvir/ledipasvir fixed-dose combination in iranian patients with chronic hepatitis C virus infection. Hepatitis Monthly. 2017;17(6).
  • 25. Welzel TM, Petersen J, Herzer K, Ferenci P, Gschwantler M, Wedemeyer H, et al. Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort. Gut. 2016;65(11):1861-70. doi: 10.1136/gutjnl-2016-312444. [PubMed: 27605539]. [PubMed Central: PMC5099229].
  • 26. Sajjad SF, Ahmad W, Hussain Jaffery SS, Asif M, Alam SE. Treatment of chronic Hepatitis C in Thalassemia major patients. J Pak Med Assoc. 2017;67(6):926-8. [PubMed: 28585595].
  • 27. Tabatabaei SV, Alavian SM, Keshvari M, Behnava B, Miri SM, Karimi Elizee P, et al. Low dose ribavirin for treatment of hepatitis C virus infected thalassemia major patients; new indications for combination therapy. Hepat Mon. 2012;12(6):372-81. doi: 10.5812/hepatmon.6592. [PubMed: 22879826]. [PubMed Central: PMC3412553].
  • 28. Mangia A, Sarli R, Gamberini R, Piga A, Cenderello G, Piazzolla V, et al. Randomised clinical trial: sofosbuvir and ledipasvir in patients with transfusion-dependent thalassaemia and HCV genotype 1 or 4 infection. Aliment Pharmacol Ther. 2017;46(4):424-31. doi: 10.1111/apt.14197. [PubMed: 28660640].
  • 29. Hezode C, Colombo M, Bourliere M, Spengler U, Ben-Ari Z, Strasser SI, et al. Elbasvir/Grazoprevir for Patients With Hepatitis C Virus Infection and Inherited Blood Disorders: A Phase III Study. Hepatology. 2017;66(3):736-45. doi: 10.1002/hep.29139. [PubMed: 28256747].
  • 30. Yang YM, Choi EJ. Efficacy and safety outcomes of sofosbuvir-based treatment regimens for hepatitis C virus-infected patients with or without cirrhosis from phase III clinical trials. Ther Clin Risk Manag. 2017;13:477-97. doi: 10.2147/TCRM.S134818. [PubMed: 28442915]. [PubMed Central: PMC5395279].
  • 31. European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol. 2017;66(1):153-94. doi: 10.1016/j.jhep.2016.09.001. [PubMed: 27667367].
  • 32. Leroy V, Angus P, Bronowicki JP, Dore GJ, Hezode C, Pianko S, et al. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+). Hepatology. 2016;63(5):1430-41. doi: 10.1002/hep.28473. [PubMed: 26822022]. [PubMed Central: PMC5069621].
  • 33. Poordad F, Schiff ER, Vierling JM, Landis C, Fontana RJ, Yang R, et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology. 2016;63(5):1493-505. doi: 10.1002/hep.28446. [PubMed: 26754432]. [PubMed Central: PMC5069651].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments